Current Protein & Peptide Science

Targeting Ovarian Solid Tumors by Elastin-Like Polypeptide Drug Conjugates: Current Trends and Future Prospectives

Background: Ovarian cancer is one of the leading causes of death worldwide. Polymers have low cytotoxicity and high functionalizability and are hence used for drug delivery systems, tissue engineering, and polymer therapeutics. In drug delivery systems, polymer-drug conjugates have shown considerable promise, especially in anticancer chemotherapy. Objective: Anticancer Drug Delivery Systems (DDS) deliver drugs to the tumor site leading to reduced exposure of the drugs to healthy cells and hence reduced side effects. Efforts have been made in the past to develop effective DDS using stimuli-responsive polymers like thermosensitive and pH-sensitive polymers. Conclusion: Elastin-like Polypeptides (ELP), one of the thermoresponsive polymers, have been identified as drug carriers in anticancer therapy. ELP-drug conjugates have the potential and can be used effectively in combination with hyperthermia for targeting drugs to solid tumors. This review reports on the use of ELPs in cancer therapy, its biomedical applications, and recent developments to target drugs to ovarian solid tumors.

Emerging Protein Biomarkers in Epithelial Ovarian Cancer Prognosis: An Aid for Multivariate Indexing

Epithelial ovarian cancer (EOC) is a chronic and degenerative disease propelled by a mutation in BRCA1/2 genes, familial history, smoking and polycystic ovary syndrome. Although the lifetime risk of ovarian cancer is low, yet it is the fifth leading cause of cancer-related deaths. Surprisingly, EOC represents 90% of all ovarian cancers, out of which 70% of women are diagnosed with the malignancy at its advanced III-IV stages. Early detection may increase the life expectancy up to 5 years. Thus, it has become the need of the hour to attain improvement of clinical outcomes of EOC and improve the life expectancy of patients. A plethora of proteins in different biological fluids may serve as prospective identifiers for the disease. Over the years, accurate identification of proteins secreted by EOC cells has been perfected by in vitro and in silico state-of-theart technologies. Multivariate test, consisting of histo-pathological data in combination with protein biomarker panel has paved way for enhanced and accurate assessment of EOC; still, there is a chance of further improvement. This review encompasses the advances made in ovarian cancer biomarker discovery and demonstrates their potential usefulness for the design of early diagnostics of EOC.

MicroRNA, a Promising Biomarker for Breast and Ovarian Cancer: A Review

Background: MicroRNAs (miRNA) belong to the substantial class of posttranscriptional gene regulators with decisive functions in typical cellular and disease progressions. They are short RNA molecules that are not translated into proteins but bind to the complementary sites of various mRNAs, thus blocking them and leading to translational inhibition. Objective: These miRNA molecules act as signatory molecules or biomarkers for various types of malignancies. Different miRNAs are involved in different cancer-linked pathways depending on the nature, stage, and kind of cancer. The objective of this article is to discuss and review the role and significance of various miRNAs in two of the most prominent cancers; breast and ovarian cancer. Methods: The role of miRNAs in the instigation, propagation, and metastasis of melanoma has been elucidated. Results: This article focuses on the up- and down-regulation of various miRNAs in breast and ovarian cancer, with stress on diversity in their occurrence and specificity in their threshold levels in certain types and stages of cancer, suggesting their potential role as an effective diagnostic and treatment tool for cancer. Conclusion: Considering all the aforementioned information, it can be concluded that miRNAs can act as potential biomarkers for the diagnosis of breast and ovarian cancers.

T-Box Transcription Factor 2 Enhances Chemoresistance of Endometrial Cancer by Mediating NRF2 Expression

Background:The roles of T-Box transcription factor (TBX2) in endometrial cancer are still not clear. This study was designed to explore the roles of TBX2 in endometrial cancer and the underlying mechanisms.Methods:The knockdown and overexpression of TBX2 in endometrial cancer cell lines were constructed by using lentivirus transduction. The xenograft animal model was established by using stable endometrial cancer cell lines. Cell viability was determined by the CCK-8 assay. The mRNA and protein levels of target genes were determined by using qPCR and Western blotting, respectively. ChIP assay was used to determine the interactions between TBX2 and nuclear factor erythroid 2-related factor 2 (NRF2).Results:The upregulation of TBX2 was observed in endometrial cancer tissues from patients with Cisplatin-resistance and Cisplatin-resistant cells. Interestingly, TBX2 regulated cell viability and Cisplatin resistance of endometrial cancer cells. In addition, the regulatory effects of TBX2 on chemo-resistance of endometrial cancer cells were associated with the NRF2 signaling pathways. Consistently, the endometrial cancer xenograft animal model revealed that TBX2 regulated tumor growth and Cisplatin resistance, and its regulatory effects were in part by the regulation of NRF2 signaling pathways.Conclusion:TBX 2 enhanced Cisplatin resistance of endometrial cancer by regulating the NRF2 signaling pathways.